Effects of Coffee Consumption, Smoking, and Hormones on Risk for Primary Sclerosing Cholangitis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 6, 2014, Pages 1019-1028

  Andersen, Ina Marie ^a   Tengesdal, Guro ^a   Lie, Benedicte Alexandra ^a,b   Boberg, Kirsten Muri ^a,b   Karlsen, Tom Hemming ^a,c   Hov, Johannes Roksund ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Coffee; Pregnancy; Primary sclerosing cholangitis; Smoking

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; HORMONE; COFFEE;

ABDOMINAL INFECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; APPENDECTOMY; ARTICLE; CELIAC DISEASE; COFFEE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FARM ANIMAL; FEMALE; GEOGRAPHIC DISTRIBUTION; HORMONAL CONTRACEPTION; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCUPATIONAL EXPOSURE; OSTEOPOROSIS; PASSIVE SMOKING; PRIMARY SCLEROSING CHOLANGITIS; PSORIASIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE HEALTH; SARCOIDOSIS; SEX DIFFERENCE; SMOKING; TONSILLECTOMY; ADOLESCENT; AGED; CHOLANGITIS, SCLEROSING; DISEASE PREDISPOSITION; MIDDLE AGED; NORWAY; PHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHOLANGITIS, SCLEROSING; COFFEE; COHORT STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; HORMONES; HUMANS; MALE; MIDDLE AGED; NORWAY; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SMOKING; YOUNG ADULT;

EID: 84901244524     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.09.024     Document Type: Article

References (58)

1. Karlsen T.H., Schrumpf E., Boberg K.M. Update on primary sclerosing cholangitis. Dig Liver Dis 2010, 42:390-400.
2. Saarinen S., Olerup O., Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:3195-3199.
3. Lamberts L.E., Janse M., Haagsma E.B., et al. Immune-mediated diseases in primary sclerosing cholangitis. Dig Liver Dis 2011, 43:802-806.
4. Saich R., Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008, 14:331-337.
5. Okolicsanyi L., Fabris L., Viaggi S., et al. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996, 8:685-691.
6. Takikawa H., Takamori Y., Tanaka A., et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan. Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004, 29:153-159.
7. Boberg K.M., Aadland E., Jahnsen J., et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
8. Kingham J.G., Kochar N., Gravenor M.B. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004, 126:1929-1930.
9. Bambha K., Kim W.R., Talwalkar J., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
10. Kaplan G.G., Laupland K.B., Butzner D., et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007, 102:1042-1049.
11. Takikawa H., Manabe T. Primary sclerosing cholangitis in Japan: analysis of 192 cases. JGastroenterol 1997, 32:134-137.
12. Escorsell A., Pares A., Rodes J., et al. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. JHepatol 1994, 21:787-791.
13. Hurlburt K.J., McMahon B.J., Deubner H., et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002, 97:2402-2407.
14. Bergquist A., Montgomery S.M., Bahmanyar S., et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008, 6:939-943.
15. Folseraas T., Melum E., Rausch P., et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. JHepatol 2012, 57:366-375.
16. Liu J.Z., Hov J.R., Folseraas T., et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013, 45:670-675.
17. Melum E., Franke A., Schramm C., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011, 43:17-19.
18. Hov J.R., Lleo A., Selmi C., et al. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. JHepatol 2010, 52:712-717.
19. Mitchell S.A., Thyssen M., Orchard T.R., et al. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002, 51:567-573.
20. Loftus E.V., Sandborn W.J., Tremaine W.J., et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996, 110:1496-1502.
21. van Erpecum K.J., Smits S.J., van de Meeberg P.C., et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996, 110:1503-1506.
22. Rutgeerts P., D'Haens G., Hiele M., et al. Appendectomy protects against ulcerative colitis. Gastroenterology 1994, 106:1251-1253.
23. Russel M.G., Dorant E., Brummer R.J., et al. Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 1997, 113:377-382.
24. Munger K.L., Levin L.I., Hollis B.W., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
25. Ng S.C., Bernstein C.N., Vatn M.H., et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013, 62:630-649.
26. Sugiyama D., Nishimura K., Tamaki K., et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010, 69:70-81.
27. Gershwin M.E., Selmi C., Worman H.J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
28. Chapman R.W., Arborgh B.A., Rhodes J.M., et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980, 21:870-877.
29. Hedstrom A.K., Baarnhielm M., Olsson T., et al. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009, 73:696-701.
30. Lund E., Dumeaux V., Braaten T., et al. Cohort profile: The Norwegian Women and Cancer Study-NOWAC-Kvinner og kreft. Int J Epidemiol 2008, 37:36-41.
31. Maniaol A.H., Brunborg C., Tallaksen C.M. Development and validation of a self-administered questionnaire for myasthenia gravis patients. Neuroepidemiology 2010, 34:253-261.
32. Krokstad S., Langhammer A., Hveem K., et al. Cohort profile: The HUNT Study, Norway. Int J Epidemiol 2013, 42:968-977.
33. Pugliatti M., Casetta I., Drulovic J., et al. Aquestionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q). Acta Neurol Scand Suppl 2012, 43-50.
34. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
35. Leitzmann M.F., Willett W.C., Rimm E.B., et al. Aprospective study of coffee consumption and the risk of symptomatic gallstone disease in men. JAMA 1999, 281:2106-2112.
36. Lillemoe K.D., Magnuson T.H., High R.C., et al. Caffeine prevents cholesterol gallstone formation. Surgery 1989, 106:400-406. discussion 406-407.
37. Nilssen O., Forde O.H., Brenn T. The Tromso Study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 1990, 132:318-326.
38. Honjo S., Kono S., Coleman M.P., et al. Coffee consumption and serum aminotransferases in middle-aged Japanese men. JClin Epidemiol 2001, 54:823-829.
39. Torres D.M., Harrison S.A. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology 2013, 144:670-672.
40. Bravi F., Bosetti C., Tavani A., et al. Coffee drinking and hepatocellular carcinoma: an update. Hepatology 2009, 50:1317-1318.
41. Freedman N.D., Everhart J.E., Lindsay K.L., et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009, 50:1360-1369.
42. Molloy J.W., Calcagno C.J., Williams C.D., et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012, 55:429-436.
43. Masterton G.S., Hayes P.C. Coffee and the liver: a potential treatment for liver disease?. Eur J Gastroenterol Hepatol 2010, 22:1277-1283.
44. Moreno M.G., Chavez E., Aldaba-Muruato L.R., et al. Coffee prevents CCl(4)-induced liver cirrhosis in the rat. Hepatol Int 2011, 5:857-863.
45. Fukushima Y., Kasuga M., Nakao K., et al. Effects of coffee on inflammatory cytokine gene expression in mice fed high-fat diets. JAgric Food Chem 2009, 57:11100-11105.
46. Freedman N.D., Park Y., Abnet C.C., et al. Association of coffee drinking with total and cause-specific mortality. NEngl J Med 2012, 366:1891-1904.
47. Ascherio A., Weisskopf M.G., O'Reilly E.J., et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004, 160:977-984.
48. Persson P.G., Ahlbom A., Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992, 3:47-52.
49. Cohen A.B., Lee D., Long M.D., et al. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci 2013, 58:1322-1328.
50. Berger J., Wynder E.L. The correlation of epidemiological variables. JClin Epidemiol 1994, 47:941-952.
51. Smits P., Temme L., Thien T. The cardiovascular interaction between caffeine and nicotine in humans. Clin Pharmacol Ther 1993, 54:194-204.
52. Lakatos P.L., Szamosi T., Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly?. World J Gastroenterol 2007, 13:6134-6139.
53. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
54. Heneghan M.A., Norris S.M., O'Grady J.G., et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001, 48:97-102.
55. Poupon R., Chretien Y., Chazouilleres O., et al. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. JHepatol 2005, 42:418-419.
56. Wellge B.E., Sterneck M., Teufel A., et al. Pregnancy in primary sclerosing cholangitis. Gut 2011, 60:1117-1121.
57. Mendes F.D., Jorgensen R., Keach J., et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006, 101:2070-2075.
58. Bo K., Thoresen M., Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology 2008, 216:40-45.